Published in Arterioscler Thromb Vasc Biol on April 03, 2003
Role of tissue factor and protease-activated receptors in a mouse model of endotoxemia. Blood (2003) 2.20
Tissue factor: a mediator of inflammatory cell recruitment, tissue injury, and thrombus formation in experimental colitis. J Exp Med (2007) 1.27
New insights into the protein C pathway: potential implications for the biological activities of drotrecogin alfa (activated). Crit Care (2005) 1.24
Acute internalization of gap junctions in vascular endothelial cells in response to inflammatory mediator-induced G-protein coupled receptor activation. FEBS Lett (2008) 1.11
Thrombin induces fibroblast CCL2/JE production and release via coupling of PAR1 to Galphaq and cooperation between ERK1/2 and Rho kinase signaling pathways. Mol Biol Cell (2008) 1.04
Thrombin-dependent NF-{kappa}B activation and monocyte/endothelial adhesion are mediated by the CARMA3·Bcl10·MALT1 signalosome. J Biol Chem (2010) 1.01
Protease-activated receptor-2 modulates protease-activated receptor-1-driven neointimal hyperplasia. Arterioscler Thromb Vasc Biol (2011) 0.95
Mandatory role of proteinase-activated receptor 1 in experimental bladder inflammation. BMC Physiol (2007) 0.91
Platelets and their chemokines in atherosclerosis-clinical applications. Front Physiol (2014) 0.91
Strain-dependent embryonic lethality and exaggerated vascular remodeling in heparin cofactor II-deficient mice. J Clin Invest (2007) 0.85
Over-expression of the thrombin receptor (PAR-1) in the placenta in preeclampsia: a mechanism for the intersection of coagulation and inflammation. J Matern Fetal Neonatal Med (2008) 0.84
Changes in amniotic fluid concentration of thrombin-antithrombin III complexes in patients with preterm labor: evidence of an increased thrombin generation. J Matern Fetal Neonatal Med (2009) 0.84
Molecular multitasking in the airspace: alpha1-antitrypsin takes on thrombin and plasmin. Am J Respir Cell Mol Biol (2007) 0.83
Wound healing in hemophilia B mice and low tissue factor mice. Thromb Res (2010) 0.81
Thrombin bound to a fibrin clot confers angiogenic and haemostatic properties on endothelial progenitor cells. J Cell Mol Med (2008) 0.81
Synergistic induction of mitogen-activated protein kinase phosphatase-1 by thrombin and epidermal growth factor requires vascular endothelial growth factor receptor-2. Arterioscler Thromb Vasc Biol (2010) 0.78
The adaptor CRADD/RAIDD controls activation of endothelial cells by proinflammatory stimuli. J Biol Chem (2014) 0.78
Unchecked thrombin is bad news for troubled arteries. J Clin Invest (2007) 0.77
Protease-Activated Receptor 1 Contributes to Angiotensin II-Induced Cardiovascular Remodeling and Inflammation. Cardiology (2016) 0.76
Dendritic cell PAR1-S1P3 signalling couples coagulation and inflammation. Nature (2008) 3.14
Role of tissue factor and protease-activated receptors in a mouse model of endotoxemia. Blood (2003) 2.20
Induction of intestinal inflammation in mouse by activation of proteinase-activated receptor-2. Am J Pathol (2002) 2.16
Role for protease activity in visceral pain in irritable bowel syndrome. J Clin Invest (2007) 2.09
Protease-activated receptor-1 contributes to cardiac remodeling and hypertrophy. Circulation (2007) 1.97
Increased local expression of coagulation factor X contributes to the fibrotic response in human and murine lung injury. J Clin Invest (2009) 1.96
Mer receptor tyrosine kinase signaling participates in platelet function. Arterioscler Thromb Vasc Biol (2004) 1.67
Proteinase-activated receptors, targets for kallikrein signaling. J Biol Chem (2006) 1.63
Blocking the protease-activated receptor 1-4 heterodimer in platelet-mediated thrombosis. Circulation (2006) 1.60
Estrogen transactivates EGFR via the sphingosine 1-phosphate receptor Edg-3: the role of sphingosine kinase-1. J Cell Biol (2006) 1.52
Protease-activated receptor (PAR) 2, but not PAR1, signaling promotes the development of mammary adenocarcinoma in polyoma middle T mice. Cancer Res (2008) 1.50
A major role for proteolytic activity and proteinase-activated receptor-2 in the pathogenesis of infectious colitis. Proc Natl Acad Sci U S A (2005) 1.45
Role of protease activated receptor 1 and 2 signaling in hypoxia-induced angiogenesis. Arterioscler Thromb Vasc Biol (2007) 1.33
Protection against acute pancreatitis by activation of protease-activated receptor-2. Am J Physiol Gastrointest Liver Physiol (2004) 1.29
Proteinase-activated receptor 2 modulates neuroinflammation in experimental autoimmune encephalomyelitis and multiple sclerosis. J Exp Med (2006) 1.25
Proinflammatory role of proteinase-activated receptor-2 in humans and mice during cutaneous inflammation in vivo. FASEB J (2003) 1.22
Blockade of the thrombin receptor protease-activated receptor-1 with a small-molecule antagonist prevents thrombus formation and vascular occlusion in nonhuman primates. J Pharmacol Exp Ther (2003) 1.20
Protective role for protease-activated receptor-2 against influenza virus pathogenesis via an IFN-gamma-dependent pathway. J Immunol (2009) 1.19
Retracted A role for proteinase-activated receptor-1 in inflammatory bowel diseases. J Clin Invest (2004) 1.15
The nucleotide-binding site of human sphingosine kinase 1. J Biol Chem (2002) 1.14
Participation of protease-activated receptor-1 in thrombin-induced microglial activation. J Neurochem (2002) 1.12
In-depth study of tripeptide-based alpha-ketoheterocycles as inhibitors of thrombin. Effective utilization of the S1' subsite and its implications to structure-based drug design. J Med Chem (2005) 1.12
Plasmin induces Cyr61 gene expression in fibroblasts via protease-activated receptor-1 and p44/42 mitogen-activated protein kinase-dependent signaling pathway. Arterioscler Thromb Vasc Biol (2002) 1.10
Characterization of thrombin-induced leukocyte rolling and adherence: a potential proinflammatory role for proteinase-activated receptor-4. J Immunol (2002) 1.10
Neutrophil cathepsin G promotes detachment-induced cardiomyocyte apoptosis via a protease-activated receptor-independent mechanism. J Biol Chem (2003) 1.10
Protease-activated receptor-2 activation: a major role in the pathogenesis of Porphyromonas gingivalis infection. Am J Pathol (2006) 1.07
Proteinase-activated receptor-2 induction by neuroinflammation prevents neuronal death during HIV infection. J Immunol (2005) 1.04
Expression of protease-activated receptor-1, -2, -3, and -4 in control and experimentally inflamed mouse bladder. Am J Pathol (2003) 1.04
Multiple mechanisms of vascular smooth muscle relaxation by the activation of proteinase-activated receptor 2 in mouse mesenteric arterioles. Br J Pharmacol (2002) 1.03
Urotensin II is a nitric oxide-dependent vasodilator and natriuretic peptide in the rat kidney. Am J Physiol Renal Physiol (2003) 1.00
Mechanisms of protease-activated receptor-4 actions in cardiomyocytes. Role of Src tyrosine kinase. J Biol Chem (2003) 0.99
Plasmin-mediated activation of platelets occurs by cleavage of protease-activated receptor 4. J Biol Chem (2004) 0.97
Potent, small-molecule inhibitors of human mast cell tryptase. Antiasthmatic action of a dipeptide-based transition-state analogue containing a benzothiazole ketone. J Med Chem (2003) 0.96
A novel, potent dual inhibitor of the leukocyte proteases cathepsin G and chymase: molecular mechanisms and anti-inflammatory activity in vivo. J Biol Chem (2005) 0.96
Regulatory network of inflammation downstream of proteinase-activated receptors. BMC Physiol (2007) 0.93
Proteinase-activated receptor-2 exerts protective and pathogenic cell type-specific effects in Alzheimer's disease. J Immunol (2007) 0.93
Dual inhibition of cathepsin G and chymase is effective in animal models of pulmonary inflammation. Am J Respir Crit Care Med (2009) 0.92
Proteinase-activated receptor-2 (PAR2): vascular effects of a PAR2-derived activating peptide via a receptor different than PAR2. J Pharmacol Exp Ther (2002) 0.92
Mandatory role of proteinase-activated receptor 1 in experimental bladder inflammation. BMC Physiol (2007) 0.91
An assay for sphingosine kinase activity using biotinylated sphingosine and streptavidin-coated membranes. Anal Biochem (2004) 0.91
Functional informatics: convergence and integration of automation and bioinformatics. Pharmacogenomics (2004) 0.91
Therapeutic potential of protease-activated receptor-1 antagonists. Expert Opin Investig Drugs (2003) 0.89
Novel bis(indolyl)maleimide pyridinophanes that are potent, selective inhibitors of glycogen synthase kinase-3. Bioorg Med Chem Lett (2007) 0.89
Proteinase-activated receptor-1 is an anti-inflammatory signal for colitis mediated by a type 2 immune response. Inflamm Bowel Dis (2005) 0.89
RWJ-58259: a selective antagonist of protease activated receptor-1. Cardiovasc Drug Rev (2003) 0.87
The use of formic acid to embellish amyloid plaque detection in Alzheimer's disease tissues misguides key observations. Neurosci Lett (2003) 0.86
Lipofuscin and Abeta42 exhibit distinct distribution patterns in normal and Alzheimer's disease brains. Neurosci Lett (2002) 0.86
Intrathecal administration of proteinase-activated receptor-2 agonists produces hyperalgesia by exciting the cell bodies of primary sensory neurons. J Pharmacol Exp Ther (2007) 0.86
Mechanisms underlying the nociceptive and inflammatory responses induced by trypsin in the mouse paw. Eur J Pharmacol (2007) 0.86
Arterial antithrombotic activity of rivaroxaban, an orally active factor Xa inhibitor, in a rat electrolytic carotid artery injury model of thrombosis. Blood Coagul Fibrinolysis (2011) 0.85
Discovery of potent peptide-mimetic antagonists for the human thrombin receptor, protease-activated receptor-1 (PAR-1). Curr Med Chem Cardiovasc Hematol Agents (2003) 0.85
Structure-function analysis of urotensin II and its use in the construction of a ligand-receptor working model. Angew Chem Int Ed Engl (2002) 0.85
Activation of proteinase-activated receptor-1 inhibits neurally evoked chloride secretion in the mouse colon in vitro. Am J Physiol Gastrointest Liver Physiol (2004) 0.84
Serine protease inhibition reduces post-ischemic granulocyte recruitment in mouse intestine. Am J Pathol (2011) 0.84
Thrombin receptor: An endogenous inhibitor of inflammatory pain, activating opioid pathways. Pain (2009) 0.84
Characterization of functional urotensin II receptors in human skeletal muscle myoblasts: comparison with angiotensin II receptors. Peptides (2005) 0.82
Contribution of bone marrow-derived cells to the pro-inflammatory effects of protease-activated receptor-2 in colitis. Inflamm Res (2010) 0.82
A novel serine protease predominately expressed in macrophages. Biochem J (2003) 0.81
Macrocyclic bisindolylmaleimides as inhibitors of protein kinase C and glycogen synthase kinase-3. Bioorg Med Chem Lett (2003) 0.81
Nonpeptide inhibitors of cathepsin G: optimization of a novel beta-ketophosphonic acid lead by structure-based drug design. J Am Chem Soc (2002) 0.81
A role for proteinase-activated receptor-1 in inflammatory bowel diseases. J Clin Invest (2006) 0.80
Pharmacological characterization of RWJ-676070, a dual vasopressin V(1A)/V(2) receptor antagonist. Eur J Pharmacol (2008) 0.80
Synthesis and SAR of pyridazinone-substituted phenylalanine amide alpha4 integrin antagonists. Bioorg Med Chem Lett (2008) 0.80
3-(7-Azaindolyl)-4-arylmaleimides as potent, selective inhibitors of glycogen synthase kinase-3. Bioorg Med Chem Lett (2004) 0.79
Synthesis and biological evaluation of novel pyridazinone-based alpha4 integrin receptor antagonists. J Med Chem (2006) 0.79
High-throughput siRNA-based functional target validation. J Biomol Screen (2004) 0.79
Integrated expressional analysis: application to the drug discovery process. Methods (2005) 0.78
High-affinity thrombin receptor (PAR-1) ligands: a new generation of indole-based peptide mimetic antagonists with a basic amine at the C-terminus. Bioorg Med Chem Lett (2003) 0.78
Aza-bicyclic amino acid carboxamides as alpha4beta1/alpha4beta7 integrin receptor antagonists. Bioorg Med Chem (2005) 0.77
Characterization of RWJ-351647, a novel nonpeptide vasopressin V2 receptor antagonist. Clin Exp Pharmacol Physiol (2006) 0.77
Potent nonpeptide vasopressin receptor antagonists based on oxazino- and thiazinobenzodiazepine templates. Bioorg Med Chem Lett (2004) 0.77
Gene expression analysis for high throughput screening applications. Comb Chem High Throughput Screen (2004) 0.77
Cooperative antithrombotic effect from the simultaneous inhibition of thrombin and factor Xa. Blood Coagul Fibrinolysis (2010) 0.77
Selection of a 2-azabicyclo[2.2.2]octane-based alpha4beta1 integrin antagonist as an inhaled anti-asthmatic agent. Bioorg Med Chem (2006) 0.77
Proteinase-activated receptor-1 (PAR-1) activation contracts the isolated human renal artery in vitro. Br J Pharmacol (2003) 0.76
Novel indolylindazolylmaleimides as inhibitors of protein kinase C-beta: synthesis, biological activity, and cardiovascular safety. J Med Chem (2005) 0.76
Piperidine-containing beta-arylpropionic acids as potent antagonists of alphavbeta3/alphavbeta5 integrins. Bioorg Med Chem Lett (2004) 0.75
Synthesis and biological evaluation of type VI beta-turn templated RGD peptidomimetics. Bioorg Med Chem Lett (2006) 0.75
1,2,3,4-Tetrahydroquinoline-containing alphaVbeta3 integrin antagonists with enhanced oral bioavailability. Bioorg Med Chem Lett (2004) 0.75
Virus-based expression systems facilitate rapid target in vivo functionality validation and high-throughput screening. J Biomol Screen (2003) 0.75
Bridged bicyclic vasopressin receptor antagonists with V(2)-selective or dual V(1a)/V(2) activity. Bioorg Med Chem Lett (2002) 0.75
Synthesis and biological evaluation of novel indoloazepine derivatives as non-peptide vasopressin V2 receptor antagonists. Bioorg Med Chem Lett (2003) 0.75
Aza-bicyclic amino acid sulfonamides as alpha(4)beta(1)/alpha(4)beta(7) integrin antagonists. Bioorg Med Chem Lett (2004) 0.75